{"ticker": {"uuid": "55c04f12-7480-4b42-80e6-bdfca7db7d55", "symbol": "CCCC", "name": "C4 Therapeutics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "C4 Therapeutics (NASDAQ: CCCC) CMO gains shares via RSU vesting, withholds some for taxes", "summary": "C4 Therapeutics' Chief Medical Officer, Leonard Reyno, acquired 15,325 shares of common stock on July 10, 2026, due to the vesting of restricted stock units. The company withheld 7,397 shares to cover tax obligations, valuing these shares at $4.06 each, a transaction noted not to", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-6388e96ad890.html", "source_name": "Stock Titan", "published_at": "2026-07-14T02:40:25", "published_display": "14 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "C4 Therapeutics (CCCC) Status Update Summary", "summary": "C4 Therapeutics provided a status update on July 8, 2026, highlighting the prioritization of their drug Cemsidomide as a class-leading IKZF1/3 degrader for multiple myeloma. The drug shows promise with a projected peak revenue of $2.5\u2013$4 billion in relapsed/refractory multiple my", "url": "https://quartr.com/events/c4-therapeutics-cccc-status-update_FkM1md6W", "source_name": "Quartr", "published_at": "2026-07-09T02:09:34", "published_display": "09 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know", "summary": "C4 Therapeutics, Inc. (CCCC) has seen a 2.65% increase in its stock price over the past week, outperforming the S&P 500 significantly over longer periods. The company holds a Zacks Momentum Style Score of A and a Zacks Rank of #2 (Buy), indicating strong short-term potential. Thi", "url": "https://finance.yahoo.com/markets/stocks/articles/c4-therapeutics-inc-cccc-2-160003458.html", "source_name": "Market source", "published_at": "2026-07-03T16:10:18", "published_display": "03 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?", "summary": "C4 Therapeutics (CCCC) experienced a 16% gain over the past month, primarily due to positive phase 1 clinical trial data for its drug candidate Cemsidomide. The drug, targeting relapsed/refractory multiple myeloma, showed a 53% overall response rate in heavily pretreated patients", "url": "https://finance.yahoo.com/healthcare/articles/c4-therapeutics-cccc-gains-over-131155541.html", "source_name": "Market source", "published_at": "2026-07-03T13:10:18", "published_display": "03 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCCC - C4 Therapeutics Inc Options", "summary": "This article provides an in-depth financial overview of C4 Therapeutics Inc. (CCCC), including its latest stock performance, key financial metrics, valuation ratios, and ownership data. It details the company's market capitalization, income, sales, earnings per share, and analyst", "url": "https://finviz.com/stock?t=CCCC&ta=1&p=w&ty=oc&b=2&r=y2&ov=list_strike&s=6", "source_name": "Finviz", "published_at": "2026-07-03T11:40:09", "published_display": "03 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCCC - C4 Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for C4 Therapeutics Inc (CCCC), including stock performance data, key financial metrics, and insider/institutional ownership details. As of July 2nd, the stock closed at $4.30 with a slight decrease, and the company has a ma", "url": "https://finviz.com/stock?t=CCCC&ta=1&p=w&ty=lf&b=2&r=y2&page=5", "source_name": "Finviz", "published_at": "2026-07-02T23:39:35", "published_display": "02 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director of C4 Therapeutics (NASDAQ: CCCC) receives 2,650-share stock award", "summary": "Kenneth Carl Anderson, a director at C4 Therapeutics (NASDAQ: CCCC), received a stock award of 2,650 common shares on July 1, 2026. This award, valued at $4.34 per share, was issued in lieu of cash compensation for his board service, aligning with the company's Non-Employee Direc", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-550b2323a641.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:16", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at C4 Therapeutics (CCCC) takes 3,341 shares as fees", "summary": "C4 Therapeutics director Donna Roy Grogan received a grant of 3,341 shares of common stock on July 1, 2026. The shares, valued at $4.34 each, were issued under the company\u2019s Non-Employee Director Compensation Policy as she elected stock in lieu of cash fees, increasing her direct", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-55a0d37d6a04.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:16", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of C4 Therapeutics, Inc. \u2013 NASDAQ:CCCC", "summary": "This article provides access to the \"Price to book forward\" financial metric for C4 Therapeutics, Inc. (NASDAQ: CCCC) through TradingView. It highlights that this data is part of the financials section for the company on the platform. The content is essentially a gateway to a spe", "url": "https://www.tradingview.com/symbols/NASDAQ-CCCC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T05:39:24", "published_display": "02 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCCC Stock Climbs As C4 Therapeutics Posts Strong Phase 1 Myeloma Data", "summary": "C4 Therapeutics (CCCC) stock rose by 8.62% following the release of positive updated Phase 1 data for its drug cemsidomide for relapsed/refractory multiple myeloma. The data showed a 53% overall response rate with durable and manageable safety, driving investor optimism. While th", "url": "https://stockstotrade.com/news/c4-therapeutics-inc-cccc-news-2026_06_30/", "source_name": "StocksToTrade", "published_at": "2026-06-30T17:42:17", "published_display": "30 Jun 2026 17:42", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell Small Cap Comp Value Benchmark", "summary": "C4 Therapeutics, Inc. (NasdaqGS:CCCC) has been added to the Russell Small Cap Comp Value Benchmark, among various other Russell indexes. This inclusion highlights the company's growing presence in the financial markets. C4 Therapeutics is a clinical-stage biopharmaceutical compan", "url": "https://www.marketscreener.com/news/c4-therapeutics-inc-nasdaqgs-cccc-added-to-russell-small-cap-comp-value-benchmark-ce7f5fdfd08cf026", "source_name": "marketscreener.com", "published_at": "2026-06-28T22:10:16", "published_display": "28 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) director awarded 62,000 stock options at $4.25 strike", "summary": "C4 Therapeutics director Laura Bessen was granted 62,000 stock options at an exercise price of $4.25 per share, expiring on June 23, 2036. This is a compensation award, not an open-market trade, and the options will vest on the earlier of June 24, 2027, or the company\u2019s next annu", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-49c560058841.html", "source_name": "Stock Titan", "published_at": "2026-06-27T08:41:17", "published_display": "27 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Steven Hoerter gets 62,000 C4 Therapeutics (CCCC) options at $4.25", "summary": "C4 Therapeutics Director Steven L. Hoerter was granted 62,000 stock options with an exercise price of $4.25 per share, expiring on June 23, 2036. These options will fully vest on the earlier of June 24, 2027, or the company\u2019s next annual stockholder meeting, provided he remains o", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-6273b45b19a7.html", "source_name": "Stock Titan", "published_at": "2026-06-27T00:39:58", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (NASDAQ: CCCC) director receives 62,000 stock options at $4.25", "summary": "C4 Therapeutics director Owen Hughes was granted 62,000 stock options with an exercise price of $4.25 per share, expiring on June 23, 2036. The options will fully vest on the earlier of June 24, 2027, or the company's next annual stockholder meeting, provided Hughes remains on th", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-9a6cb798bd34.html", "source_name": "Stock Titan", "published_at": "2026-06-27T00:09:33", "published_display": "27 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Anderson Kenneth Carl", "summary": "This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for C4 Therapeutics, filed by Director Anderson Kenneth Carl. It details changes in his holdings of the company's securities, as required by the Securities and Exchange Commission. The filing e", "url": "https://www.moomoo.com/news/notice/307613131/c4-therapeutics-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-26T21:42:17", "published_display": "26 Jun 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 C4 Therapeutics Inc For: 26 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for C4 Therapeutics Inc, specifically for activity on June 26. The content is brief, primarily serving as a notification about the regulatory filing. It includes a market data table with various indices, commodities, bond", "url": "https://ng.investing.com/news/stock-market-news/form-4-c4-therapeuticsinc-for-26-june-93CH-2576500", "source_name": "Investing.com Nigeria", "published_at": "2026-06-26T21:32:00", "published_display": "26 Jun 2026 21:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics, Inc. Actuals & Estimates (NASDAQ:CCCC)", "summary": "This article provides an overview of C4 Therapeutics, Inc. (NASDAQ: CCCC) stock, including its current price, market capitalization, and historical performance. It details financial actuals and estimates, analysts' price targets, and information on earnings reports, revenue, net ", "url": "https://www.tradingview.com/symbols/NASDAQ-CCCC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:39:58", "published_display": "26 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] C4 Therapeutics, Inc. Insider Trading Activity", "summary": "C4 Therapeutics, Inc. director Kenneth Carl Anderson was granted 62,000 stock options to buy common stock at an exercise price of $4.25 per share. The options vest in full on the earlier of June 24, 2027, or the company's next annual stockholder meeting, provided he continues to ", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-4cf1ecd7a65d.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:09:34", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (NASDAQ: CCCC) director receives grant of 62,000 stock options", "summary": "C4 Therapeutics director Utpal Koppikar was granted 62,000 stock options with an exercise price of $4.25 per share, expiring on June 23, 2036. These options will vest on the earlier of June 24, 2027, or the company's next annual stockholder meeting, provided he remains on the Boa", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-7eddf4bba924.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:09:34", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are medical stocks lagging C4 Therapeutics (CCCC) this year?", "summary": "This article from MSN discusses whether medical stocks are underperforming compared to C4 Therapeutics (CCCC) this year. The title suggests a focus on the relative stock performance within the medical sector.", "url": "https://www.msn.com/en-us/money/top-stocks/are-medical-stocks-lagging-c4-therapeutics-cccc-this-year/ar-AA23hnZN?ocid=BingNewsVerp", "source_name": "MSN", "published_at": "2026-06-26T14:09:34", "published_display": "26 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) director receives 62,000-share stock option award", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNRko1OTFra2wzQ3M4cTVjVHJtZ1ZxbWhMSW1QLWxUVUZVeHNFSjNrdl93emFtZU0tZHpaQk1fa0RVaDN2d3RqRldoc3M3VksxazNaTXlvbEFjQTFKVng0Szc1S1VUMVBVN1ByTlhpN1B5N1lqdVdHQU9FdDlPVVp5cjBYTEgzdHozdDk0eXczUmhWV25CaS13OVFBVkxya19zOWJOSm4zZzM3U3JYUXV4aXA2MA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at C4 Therapeutics (CCCC) granted 62,000 stock options at $4.25", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQaGlNNUNNTnEzVnJCMDQxckZVZUlxWXA2OUZFTHBTc01zeFZEX1lZZF9CTlVPenZEN0RXXy1QVlBKdHlja1lKUVIzUklVd2pBSVhSZi1tN2lOeVpvQXdWNG9kSG10U1doNXhwLUF6YUdRWk8tUVV4WERKOTdmYkh4WFlNY0Zybkw0SzFxNklCcTVnRWZhNDZrUDgtRlFPYi0zRHBNVU5oNmRpR1pmazZEUnlURQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) director receives grant of 62,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNSU1OaV81bFRqWjV6X0JpRVgxR3RnU3dnRndrWENKd211UXp2T2JQVmZIMndYUWY3UVhENHMtUnBSbUNJTHV2QXJDLTczcmUxSE5sUGdJUzBaaC0xUGFycFZ0RGdBaDRnOTFQczMtMmMzbkZTRlJRQkc1Tmh3bk1xalpDQjRLWElCc2FvMzRmZ0RkQWRDRVVoZldxT1MwcDhkbjlBN3haVFdkZmRQX1Y3U2dmWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (NASDAQ: CCCC) investors approve directors, pay and stock plan change", "summary": "C4 Therapeutics, Inc. (NASDAQ: CCCC) stockholders approved the election of three Class III directors (Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar) to serve until the 2029 annual meeting. They also granted non-binding, advisory approval of named executive officer c", "url": "https://www.stocktitan.net/sec-filings/CCCC/8-k-c4-therapeutics-inc-reports-material-event-1dce810a9331.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:10:54", "published_display": "24 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) AGM 2026 Summary", "summary": "This article summarizes C4 Therapeutics' (CCCC) 2026 Annual General Meeting (AGM), held on June 24, 2026. Key agenda items included the election of Class III directors, an advisory vote on executive compensation, ratification of KPMG LLP as the auditor, and an amendment to the 20", "url": "https://quartr.com/events/c4-therapeutics-inc-cccc-agm-2026_FkM1DVPJ", "source_name": "Quartr", "published_at": "2026-06-24T19:11:30", "published_display": "24 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCCC: All proposals, including director elections and stock plan amendment, passed by majority vote", "summary": "C4 Therapeutics, Inc. (CCCC) held its Annual General Meeting (AGM) where all four proposed items passed by a majority vote. These proposals included the election of directors, executive compensation, auditor ratification, and a stock plan amendment. No shareholder questions were ", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3647869:0-cccc-all-proposals-including-director-elections-and-stock-plan-amendment-passed-by-majority-vote/", "source_name": "TradingView", "published_at": "2026-06-24T13:09:40", "published_display": "24 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics Inc (CCCC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of C4 Therapeutics Inc (CCCC), detailing its current price momentum score of 8.84 and ranking within the Biotechnology & Medical Research industry. It identifies resistance at $4.67 and support at $3.51, suggesting suitability for range-", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cccc/technical", "source_name": "TradingKey", "published_at": "2026-06-23T09:40:20", "published_display": "23 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide - Slideshow (NASDAQ:CCCC) 2026-06-20", "summary": "C4 Therapeutics, Inc. (CCCC) presented a slideshow discussing the evolving landscape of multiple myeloma treatments. The presentation highlighted the significant role of IKZF1/3 degraders, including their proprietary drug, Cemsidomide. The company's insights focus on advancements", "url": "https://seekingalpha.com/article/4916492-c4-therapeutics-inc-cccc-discusses-evolving-multiple-myeloma-treatments-and-the-role-of-ikzf1", "source_name": "Seeking Alpha", "published_at": "2026-06-20T19:13:00", "published_display": "20 Jun 2026 19:13", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Are Bullish on Top Healthcare Picks", "summary": "Wall Street analysts are showing bullish sentiment towards the healthcare sector, specifically highlighting C4 Therapeutics (CCCC) and Ocular Therapeutix (OCUL). Barclays analyst Etzer Darout maintained a Buy rating on C4 Therapeutics with a $7.00 price target, and the broader St", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CCCC-Q/pressreleases/2551808/wall-street-analysts-are-bullish-on-top-healthcare-picks/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T17:10:39", "published_display": "19 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/c4-therapeutics-reports-53-response-114647340.html", "source_name": "MT Newswires", "published_at": "2026-06-11T11:46:47+00:00", "published_display": "11 Jun 2026 11:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/c4-therapeutics-presents-phase-1-110000188.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T11:00:00+00:00", "published_display": "11 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPX1pMb1pOVVo2aFdTc1gxTWluTVpFOW9SOXlWT2d6Y05DTnk5YnNHcWYtcFZQLWZKTGFSUkV6cGE3Zk0zd2QwQWZuei1IV3pZM0JvZ2Y1WllzX2RBZjRzWExfNGNTUnlfYjFQS1Exakdxei1nbVd2UDNCM2RIczZENkF4dzVrcmxxNjBibWpqT2EzLXI1LXhBNmkyUmpnZzQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCCC (NASDAQ) insider exercise-and-sale: 9,087 options sold from 29,080 grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPY0NIU1Z2M0liR1lUOVladVB5aDhhU01LcGxkZWFMbEZiUUp5alB5YS1aX2dtcXNzcmI3Tnl2VXBmck5PTXE0d2hVU255aGRCLTVCRTR2d3FjUUFxUkFDVk1HRS16bXhaVzZIUHFZYW9FLWg0czdhT3NacTlUaHd6b01KU1ZibHZ6dHpKX0hvRWNtZ3ctdDBhSllsR3o?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics to Participate in Upcoming Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/c4-therapeutics-participate-upcoming-conferences-110000482.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T11:00:00+00:00", "published_display": "20 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech C4 Therapeutics gives new hire options on 85,480 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNUUNPRkx0STJRVktSWjM2dEdwWTM3a0V3SUFleE1NNVpWem1PVFJOY3R5YzFHVFBEVDBQUk9VUm51X0FvSGNpWjFDa3dsSEswczIxZDdHb1VIcVlMQ2hIbVJHa1Ayd0laUGRXOW10V2YxY19KYUhxcklNV1RwaVJldXJNQ0xlNUVpNmMzaWI1eGZlbWlrUDFlY0dwYnJHcEZZMmNhb1BYN0FMRkFmMHhVcE1YYVlnc0dMenNFbGpfc1g?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "C4 Therapeutics (CCCC) Q1 Loss Of US$25.1 Million Reinforces Profitability Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPenV1RnpDcVRnclYtMUhOSHZrM2hnWGQwMFdsS0d4eElOSlQzSU5jSnlnSjRPSlR4RmltTk8wenIwVHd6bGM5dVZzZ0htb09XWDA4Tk5seUtmc3gtcnU4RWJCbEVLWDJzdENSbllWX2FBRS1YMzFCd0dKdk9fODhvcDJWRU5vQ0JvVXhiY1MxNTFxZ2poV1c0ZlUzMkt3RGJwT0xDdll5LXJ1Mk1KRU1heWlBWk5sVlBkUlE?oc=5", "source_name": "Investing News Network", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "C4 Therapeutics updates bylaws to designate federal courts as exclusive forums", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQY2lJbE9QQ1lRZGlIazBSZkd0cmtMSWFEc2VBM191UUFraThSLXJiRk9uRGdnd2Z4UzBNSlU3YlIxdXBIaUpTYnFhRWsxY3RvanJlZlBzNkg1bWFYblNzWEJvVzViV3MxQ1lKMUlnbWdjN1M4ZjBNU1JMMmt1SXpVeDZfR21PVTYwNXZucnZqU1pQRU9QWTZxb0JXUGctSVM3ZFV4UGxTc2pRYlhwRTRlMGtHUzhWeC10WnY5Ulo3N3ZacnZ0bDR0QldHME54OTQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOLW9LWXJ0cC01LXE5VEtTcTJhdnJXT0VTN0paZHRKUi1LR3ZyNngtUFVmWHFvS0s2MEZEajE1M1h6X1JGMjllcWE0MFktUkQ2Zl9ya3JNcFNZV0lqa1I3RzRsQTRUQU5sMTMzSUhiM2VSOHY2cDVXLUZ3RDRtejNwaUFVSU1MVnpKa3lZTkY4aGU4aFg5VEdFUGx6Mi1tdUF4dHUw?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPQlNGSVZGUU5QU09GWjBhYnBFMktPN0t1RHk4dkdhV3pWOW9KaHE2OFk5Q014YXE4M0xyWWI0bkJXUkN6ZThmVDh3dVFQYU9HMmZ3S0FFcks0RUY4SXhOYVk1YUF1aWFveW9fRW5nRjAtVzU1cFZlM1dNMFVtRHVLLW9fMFUzTzFYNFpHaWFRVlVZcEthSG1VZFk5VDI3ZDZP?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxORlNEOV9UXy1jWV94VXdjZlpJUmNVcU00VFBZUm1nMjhVaUdoWXFzX3M3VXlSNzhoZHpaRUNkMDRWenRSMUxEZ2dBU1Y1TC1RdlNSdGtzMEloR0xsY2hYQU44WTJkM0QxU3R1Q3hhZDh1Umt1eWRNcjI3TThsTFBCOWZFcU9pUjRrakE?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional investors may adopt severe steps after C4 Therapeutics, Inc.'s (NASDAQ:CCCC) latest 11% drop adds to a year losses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics Advances Cemsidomide Trials and Internal Discovery Strategy Ahead of Key Milestones Through 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQcVdxb1VVaVQ1Qmx0WDc5ME5kVHJtbjBDQU02ZVZRVlRyTjFoTmJXMm9jVEg2b0xhbWl4M0s0UU9EUEQwemJmOVN1eTUyNDJTbWwyUXJ2cHJyRFVMTzlmTkNxUHVlRE56WTN6OGF1ZW1WZWtiQ2gwM01aUjE0cV96dmQ0VngyQzZMNFBTNlMzUVFEZXAyUlVWa1ZSM20yVXpHa29wSHczTEw4RGxhNGRUd0M0Y242VloyOGY4TkFGOFVYWWdPSmhEdW5temE2dE1zNENwTkdJSU1QVXR6ZlE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOM3FiazVyTVZzR2ZSdWpyQ2dOcEhmSFpsX3BsSVY3TGRkdDVBWkthRkJxZV8yd09TcVNJQkdzWTNCU0o0QkhsVTFFam96X1N3VG1tem9NM292MzVKUm1sYmZsN2JSMnBnQjBWY3FRQXlKbDlsRkxna04wQnJMOVYzbw?oc=5", "source_name": "Market source", "published_at": "2025-12-31T08:00:00+00:00", "published_display": "31 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "C4 Therapeutics (NASDAQ: CCCC) CMO gains shares via RSU vesting, withholds some for taxes", "summary": "C4 Therapeutics' Chief Medical Officer, Leonard Reyno, acquired 15,325 shares of common stock on July 10, 2026, due to the vesting of restricted stock units. The company withheld 7,397 shares to cover tax obligations, valuing these shares at $4.06 each, a transaction noted not to", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-6388e96ad890.html", "source_name": "Stock Titan", "published_at": "2026-07-14T02:40:25", "published_display": "14 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) Status Update Summary", "summary": "C4 Therapeutics provided a status update on July 8, 2026, highlighting the prioritization of their drug Cemsidomide as a class-leading IKZF1/3 degrader for multiple myeloma. The drug shows promise with a projected peak revenue of $2.5\u2013$4 billion in relapsed/refractory multiple my", "url": "https://quartr.com/events/c4-therapeutics-cccc-status-update_FkM1md6W", "source_name": "Quartr", "published_at": "2026-07-09T02:09:34", "published_display": "09 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know", "summary": "C4 Therapeutics, Inc. (CCCC) has seen a 2.65% increase in its stock price over the past week, outperforming the S&P 500 significantly over longer periods. The company holds a Zacks Momentum Style Score of A and a Zacks Rank of #2 (Buy), indicating strong short-term potential. Thi", "url": "https://finance.yahoo.com/markets/stocks/articles/c4-therapeutics-inc-cccc-2-160003458.html", "source_name": "Market source", "published_at": "2026-07-03T16:10:18", "published_display": "03 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?", "summary": "C4 Therapeutics (CCCC) experienced a 16% gain over the past month, primarily due to positive phase 1 clinical trial data for its drug candidate Cemsidomide. The drug, targeting relapsed/refractory multiple myeloma, showed a 53% overall response rate in heavily pretreated patients", "url": "https://finance.yahoo.com/healthcare/articles/c4-therapeutics-cccc-gains-over-131155541.html", "source_name": "Market source", "published_at": "2026-07-03T13:10:18", "published_display": "03 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCCC - C4 Therapeutics Inc Options", "summary": "This article provides an in-depth financial overview of C4 Therapeutics Inc. (CCCC), including its latest stock performance, key financial metrics, valuation ratios, and ownership data. It details the company's market capitalization, income, sales, earnings per share, and analyst", "url": "https://finviz.com/stock?t=CCCC&ta=1&p=w&ty=oc&b=2&r=y2&ov=list_strike&s=6", "source_name": "Finviz", "published_at": "2026-07-03T11:40:09", "published_display": "03 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCCC - C4 Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for C4 Therapeutics Inc (CCCC), including stock performance data, key financial metrics, and insider/institutional ownership details. As of July 2nd, the stock closed at $4.30 with a slight decrease, and the company has a ma", "url": "https://finviz.com/stock?t=CCCC&ta=1&p=w&ty=lf&b=2&r=y2&page=5", "source_name": "Finviz", "published_at": "2026-07-02T23:39:35", "published_display": "02 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director of C4 Therapeutics (NASDAQ: CCCC) receives 2,650-share stock award", "summary": "Kenneth Carl Anderson, a director at C4 Therapeutics (NASDAQ: CCCC), received a stock award of 2,650 common shares on July 1, 2026. This award, valued at $4.34 per share, was issued in lieu of cash compensation for his board service, aligning with the company's Non-Employee Direc", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-550b2323a641.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:16", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at C4 Therapeutics (CCCC) takes 3,341 shares as fees", "summary": "C4 Therapeutics director Donna Roy Grogan received a grant of 3,341 shares of common stock on July 1, 2026. The shares, valued at $4.34 each, were issued under the company\u2019s Non-Employee Director Compensation Policy as she elected stock in lieu of cash fees, increasing her direct", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-55a0d37d6a04.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:16", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of C4 Therapeutics, Inc. \u2013 NASDAQ:CCCC", "summary": "This article provides access to the \"Price to book forward\" financial metric for C4 Therapeutics, Inc. (NASDAQ: CCCC) through TradingView. It highlights that this data is part of the financials section for the company on the platform. The content is essentially a gateway to a spe", "url": "https://www.tradingview.com/symbols/NASDAQ-CCCC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T05:39:24", "published_display": "02 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCCC Stock Climbs As C4 Therapeutics Posts Strong Phase 1 Myeloma Data", "summary": "C4 Therapeutics (CCCC) stock rose by 8.62% following the release of positive updated Phase 1 data for its drug cemsidomide for relapsed/refractory multiple myeloma. The data showed a 53% overall response rate with durable and manageable safety, driving investor optimism. While th", "url": "https://stockstotrade.com/news/c4-therapeutics-inc-cccc-news-2026_06_30/", "source_name": "StocksToTrade", "published_at": "2026-06-30T17:42:17", "published_display": "30 Jun 2026 17:42", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell Small Cap Comp Value Benchmark", "summary": "C4 Therapeutics, Inc. (NasdaqGS:CCCC) has been added to the Russell Small Cap Comp Value Benchmark, among various other Russell indexes. This inclusion highlights the company's growing presence in the financial markets. C4 Therapeutics is a clinical-stage biopharmaceutical compan", "url": "https://www.marketscreener.com/news/c4-therapeutics-inc-nasdaqgs-cccc-added-to-russell-small-cap-comp-value-benchmark-ce7f5fdfd08cf026", "source_name": "marketscreener.com", "published_at": "2026-06-28T22:10:16", "published_display": "28 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) director awarded 62,000 stock options at $4.25 strike", "summary": "C4 Therapeutics director Laura Bessen was granted 62,000 stock options at an exercise price of $4.25 per share, expiring on June 23, 2036. This is a compensation award, not an open-market trade, and the options will vest on the earlier of June 24, 2027, or the company\u2019s next annu", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-49c560058841.html", "source_name": "Stock Titan", "published_at": "2026-06-27T08:41:17", "published_display": "27 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Steven Hoerter gets 62,000 C4 Therapeutics (CCCC) options at $4.25", "summary": "C4 Therapeutics Director Steven L. Hoerter was granted 62,000 stock options with an exercise price of $4.25 per share, expiring on June 23, 2036. These options will fully vest on the earlier of June 24, 2027, or the company\u2019s next annual stockholder meeting, provided he remains o", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-6273b45b19a7.html", "source_name": "Stock Titan", "published_at": "2026-06-27T00:39:58", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (NASDAQ: CCCC) director receives 62,000 stock options at $4.25", "summary": "C4 Therapeutics director Owen Hughes was granted 62,000 stock options with an exercise price of $4.25 per share, expiring on June 23, 2036. The options will fully vest on the earlier of June 24, 2027, or the company's next annual stockholder meeting, provided Hughes remains on th", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-9a6cb798bd34.html", "source_name": "Stock Titan", "published_at": "2026-06-27T00:09:33", "published_display": "27 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Anderson Kenneth Carl", "summary": "This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for C4 Therapeutics, filed by Director Anderson Kenneth Carl. It details changes in his holdings of the company's securities, as required by the Securities and Exchange Commission. The filing e", "url": "https://www.moomoo.com/news/notice/307613131/c4-therapeutics-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-26T21:42:17", "published_display": "26 Jun 2026 21:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 C4 Therapeutics Inc For: 26 June By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for C4 Therapeutics Inc, specifically for activity on June 26. The content is brief, primarily serving as a notification about the regulatory filing. It includes a market data table with various indices, commodities, bond", "url": "https://ng.investing.com/news/stock-market-news/form-4-c4-therapeuticsinc-for-26-june-93CH-2576500", "source_name": "Investing.com Nigeria", "published_at": "2026-06-26T21:32:00", "published_display": "26 Jun 2026 21:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics, Inc. Actuals & Estimates (NASDAQ:CCCC)", "summary": "This article provides an overview of C4 Therapeutics, Inc. (NASDAQ: CCCC) stock, including its current price, market capitalization, and historical performance. It details financial actuals and estimates, analysts' price targets, and information on earnings reports, revenue, net ", "url": "https://www.tradingview.com/symbols/NASDAQ-CCCC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:39:58", "published_display": "26 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] C4 Therapeutics, Inc. Insider Trading Activity", "summary": "C4 Therapeutics, Inc. director Kenneth Carl Anderson was granted 62,000 stock options to buy common stock at an exercise price of $4.25 per share. The options vest in full on the earlier of June 24, 2027, or the company's next annual stockholder meeting, provided he continues to ", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-4cf1ecd7a65d.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:09:34", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (NASDAQ: CCCC) director receives grant of 62,000 stock options", "summary": "C4 Therapeutics director Utpal Koppikar was granted 62,000 stock options with an exercise price of $4.25 per share, expiring on June 23, 2036. These options will vest on the earlier of June 24, 2027, or the company's next annual stockholder meeting, provided he remains on the Boa", "url": "https://www.stocktitan.net/sec-filings/CCCC/form-4-c4-therapeutics-inc-insider-trading-activity-7eddf4bba924.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:09:34", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are medical stocks lagging C4 Therapeutics (CCCC) this year?", "summary": "This article from MSN discusses whether medical stocks are underperforming compared to C4 Therapeutics (CCCC) this year. The title suggests a focus on the relative stock performance within the medical sector.", "url": "https://www.msn.com/en-us/money/top-stocks/are-medical-stocks-lagging-c4-therapeutics-cccc-this-year/ar-AA23hnZN?ocid=BingNewsVerp", "source_name": "MSN", "published_at": "2026-06-26T14:09:34", "published_display": "26 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) director receives 62,000-share stock option award", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNRko1OTFra2wzQ3M4cTVjVHJtZ1ZxbWhMSW1QLWxUVUZVeHNFSjNrdl93emFtZU0tZHpaQk1fa0RVaDN2d3RqRldoc3M3VksxazNaTXlvbEFjQTFKVng0Szc1S1VUMVBVN1ByTlhpN1B5N1lqdVdHQU9FdDlPVVp5cjBYTEgzdHozdDk0eXczUmhWV25CaS13OVFBVkxya19zOWJOSm4zZzM3U3JYUXV4aXA2MA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at C4 Therapeutics (CCCC) granted 62,000 stock options at $4.25", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQaGlNNUNNTnEzVnJCMDQxckZVZUlxWXA2OUZFTHBTc01zeFZEX1lZZF9CTlVPenZEN0RXXy1QVlBKdHlja1lKUVIzUklVd2pBSVhSZi1tN2lOeVpvQXdWNG9kSG10U1doNXhwLUF6YUdRWk8tUVV4WERKOTdmYkh4WFlNY0Zybkw0SzFxNklCcTVnRWZhNDZrUDgtRlFPYi0zRHBNVU5oNmRpR1pmazZEUnlURQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) director receives grant of 62,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNSU1OaV81bFRqWjV6X0JpRVgxR3RnU3dnRndrWENKd211UXp2T2JQVmZIMndYUWY3UVhENHMtUnBSbUNJTHV2QXJDLTczcmUxSE5sUGdJUzBaaC0xUGFycFZ0RGdBaDRnOTFQczMtMmMzbkZTRlJRQkc1Tmh3bk1xalpDQjRLWElCc2FvMzRmZ0RkQWRDRVVoZldxT1MwcDhkbjlBN3haVFdkZmRQX1Y3U2dmWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (NASDAQ: CCCC) investors approve directors, pay and stock plan change", "summary": "C4 Therapeutics, Inc. (NASDAQ: CCCC) stockholders approved the election of three Class III directors (Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar) to serve until the 2029 annual meeting. They also granted non-binding, advisory approval of named executive officer c", "url": "https://www.stocktitan.net/sec-filings/CCCC/8-k-c4-therapeutics-inc-reports-material-event-1dce810a9331.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:10:54", "published_display": "24 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) AGM 2026 Summary", "summary": "This article summarizes C4 Therapeutics' (CCCC) 2026 Annual General Meeting (AGM), held on June 24, 2026. Key agenda items included the election of Class III directors, an advisory vote on executive compensation, ratification of KPMG LLP as the auditor, and an amendment to the 20", "url": "https://quartr.com/events/c4-therapeutics-inc-cccc-agm-2026_FkM1DVPJ", "source_name": "Quartr", "published_at": "2026-06-24T19:11:30", "published_display": "24 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCCC: All proposals, including director elections and stock plan amendment, passed by majority vote", "summary": "C4 Therapeutics, Inc. (CCCC) held its Annual General Meeting (AGM) where all four proposed items passed by a majority vote. These proposals included the election of directors, executive compensation, auditor ratification, and a stock plan amendment. No shareholder questions were ", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3647869:0-cccc-all-proposals-including-director-elections-and-stock-plan-amendment-passed-by-majority-vote/", "source_name": "TradingView", "published_at": "2026-06-24T13:09:40", "published_display": "24 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics Inc (CCCC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of C4 Therapeutics Inc (CCCC), detailing its current price momentum score of 8.84 and ranking within the Biotechnology & Medical Research industry. It identifies resistance at $4.67 and support at $3.51, suggesting suitability for range-", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cccc/technical", "source_name": "TradingKey", "published_at": "2026-06-23T09:40:20", "published_display": "23 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide - Slideshow (NASDAQ:CCCC) 2026-06-20", "summary": "C4 Therapeutics, Inc. (CCCC) presented a slideshow discussing the evolving landscape of multiple myeloma treatments. The presentation highlighted the significant role of IKZF1/3 degraders, including their proprietary drug, Cemsidomide. The company's insights focus on advancements", "url": "https://seekingalpha.com/article/4916492-c4-therapeutics-inc-cccc-discusses-evolving-multiple-myeloma-treatments-and-the-role-of-ikzf1", "source_name": "Seeking Alpha", "published_at": "2026-06-20T19:13:00", "published_display": "20 Jun 2026 19:13", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Are Bullish on Top Healthcare Picks", "summary": "Wall Street analysts are showing bullish sentiment towards the healthcare sector, specifically highlighting C4 Therapeutics (CCCC) and Ocular Therapeutix (OCUL). Barclays analyst Etzer Darout maintained a Buy rating on C4 Therapeutics with a $7.00 price target, and the broader St", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CCCC-Q/pressreleases/2551808/wall-street-analysts-are-bullish-on-top-healthcare-picks/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T17:10:39", "published_display": "19 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/c4-therapeutics-reports-53-response-114647340.html", "source_name": "MT Newswires", "published_at": "2026-06-11T11:46:47+00:00", "published_display": "11 Jun 2026 11:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/c4-therapeutics-presents-phase-1-110000188.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T11:00:00+00:00", "published_display": "11 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPX1pMb1pOVVo2aFdTc1gxTWluTVpFOW9SOXlWT2d6Y05DTnk5YnNHcWYtcFZQLWZKTGFSUkV6cGE3Zk0zd2QwQWZuei1IV3pZM0JvZ2Y1WllzX2RBZjRzWExfNGNTUnlfYjFQS1Exakdxei1nbVd2UDNCM2RIczZENkF4dzVrcmxxNjBibWpqT2EzLXI1LXhBNmkyUmpnZzQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCCC (NASDAQ) insider exercise-and-sale: 9,087 options sold from 29,080 grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPY0NIU1Z2M0liR1lUOVladVB5aDhhU01LcGxkZWFMbEZiUUp5alB5YS1aX2dtcXNzcmI3Tnl2VXBmck5PTXE0d2hVU255aGRCLTVCRTR2d3FjUUFxUkFDVk1HRS16bXhaVzZIUHFZYW9FLWg0czdhT3NacTlUaHd6b01KU1ZibHZ6dHpKX0hvRWNtZ3ctdDBhSllsR3o?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics to Participate in Upcoming Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/c4-therapeutics-participate-upcoming-conferences-110000482.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T11:00:00+00:00", "published_display": "20 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech C4 Therapeutics gives new hire options on 85,480 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNUUNPRkx0STJRVktSWjM2dEdwWTM3a0V3SUFleE1NNVpWem1PVFJOY3R5YzFHVFBEVDBQUk9VUm51X0FvSGNpWjFDa3dsSEswczIxZDdHb1VIcVlMQ2hIbVJHa1Ayd0laUGRXOW10V2YxY19KYUhxcklNV1RwaVJldXJNQ0xlNUVpNmMzaWI1eGZlbWlrUDFlY0dwYnJHcEZZMmNhb1BYN0FMRkFmMHhVcE1YYVlnc0dMenNFbGpfc1g?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) Q1 Loss Of US$25.1 Million Reinforces Profitability Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPenV1RnpDcVRnclYtMUhOSHZrM2hnWGQwMFdsS0d4eElOSlQzSU5jSnlnSjRPSlR4RmltTk8wenIwVHd6bGM5dVZzZ0htb09XWDA4Tk5seUtmc3gtcnU4RWJCbEVLWDJzdENSbllWX2FBRS1YMzFCd0dKdk9fODhvcDJWRU5vQ0JvVXhiY1MxNTFxZ2poV1c0ZlUzMkt3RGJwT0xDdll5LXJ1Mk1KRU1heWlBWk5sVlBkUlE?oc=5", "source_name": "Investing News Network", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics updates bylaws to designate federal courts as exclusive forums", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQY2lJbE9QQ1lRZGlIazBSZkd0cmtMSWFEc2VBM191UUFraThSLXJiRk9uRGdnd2Z4UzBNSlU3YlIxdXBIaUpTYnFhRWsxY3RvanJlZlBzNkg1bWFYblNzWEJvVzViV3MxQ1lKMUlnbWdjN1M4ZjBNU1JMMmt1SXpVeDZfR21PVTYwNXZucnZqU1pQRU9QWTZxb0JXUGctSVM3ZFV4UGxTc2pRYlhwRTRlMGtHUzhWeC10WnY5Ulo3N3ZacnZ0bDR0QldHME54OTQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOLW9LWXJ0cC01LXE5VEtTcTJhdnJXT0VTN0paZHRKUi1LR3ZyNngtUFVmWHFvS0s2MEZEajE1M1h6X1JGMjllcWE0MFktUkQ2Zl9ya3JNcFNZV0lqa1I3RzRsQTRUQU5sMTMzSUhiM2VSOHY2cDVXLUZ3RDRtejNwaUFVSU1MVnpKa3lZTkY4aGU4aFg5VEdFUGx6Mi1tdUF4dHUw?oc=5", "source_name": "Market source", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPQlNGSVZGUU5QU09GWjBhYnBFMktPN0t1RHk4dkdhV3pWOW9KaHE2OFk5Q014YXE4M0xyWWI0bkJXUkN6ZThmVDh3dVFQYU9HMmZ3S0FFcks0RUY4SXhOYVk1YUF1aWFveW9fRW5nRjAtVzU1cFZlM1dNMFVtRHVLLW9fMFUzTzFYNFpHaWFRVlVZcEthSG1VZFk5VDI3ZDZP?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxORlNEOV9UXy1jWV94VXdjZlpJUmNVcU00VFBZUm1nMjhVaUdoWXFzX3M3VXlSNzhoZHpaRUNkMDRWenRSMUxEZ2dBU1Y1TC1RdlNSdGtzMEloR0xsY2hYQU44WTJkM0QxU3R1Q3hhZDh1Umt1eWRNcjI3TThsTFBCOWZFcU9pUjRrakE?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional investors may adopt severe steps after C4 Therapeutics, Inc.'s (NASDAQ:CCCC) latest 11% drop adds to a year losses", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "C4 Therapeutics Advances Cemsidomide Trials and Internal Discovery Strategy Ahead of Key Milestones Through 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxQcVdxb1VVaVQ1Qmx0WDc5ME5kVHJtbjBDQU02ZVZRVlRyTjFoTmJXMm9jVEg2b0xhbWl4M0s0UU9EUEQwemJmOVN1eTUyNDJTbWwyUXJ2cHJyRFVMTzlmTkNxUHVlRE56WTN6OGF1ZW1WZWtiQ2gwM01aUjE0cV96dmQ0VngyQzZMNFBTNlMzUVFEZXAyUlVWa1ZSM20yVXpHa29wSHczTEw4RGxhNGRUd0M0Y242VloyOGY4TkFGOFVYWWdPSmhEdW5temE2dE1zNENwTkdJSU1QVXR6ZlE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOM3FiazVyTVZzR2ZSdWpyQ2dOcEhmSFpsX3BsSVY3TGRkdDVBWkthRkJxZV8yd09TcVNJQkdzWTNCU0o0QkhsVTFFam96X1N3VG1tem9NM292MzVKUm1sYmZsN2JSMnBnQjBWY3FRQXlKbDlsRkxna04wQnJMOVYzbw?oc=5", "source_name": "Market source", "published_at": "2025-12-31T08:00:00+00:00", "published_display": "31 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 53, "sentiment_summary": {"positive": 14, "negative": 3, "neutral": 36, "score": 56, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 19.6, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 12}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 14, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 4.06, "latest_week": "2026-07-10", "one_week_move": -5.6, "four_week_move": 4.1, "twelve_week_move": 39.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.378218, "market_dynamics_buy_signal": false, "relative_strength": 29.307983, "fair_value_gap": 8.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.7289, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.6% over one week, +4.1% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 14}, {"label": "Market source", "count": 12}, {"label": "simplywall.st", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "Quartr", "count": 2}, {"label": "Finviz", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "StocksToTrade", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 12}, {"label": "Balance sheet", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-5.6% over one week, +4.1% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "C4 Therapeutics (NASDAQ: CCCC) CMO gains shares via RSU vesting, withholds some for taxes"}], "updated_at": "2026-07-16T08:10:35.558394+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}